We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Christina
Aye
christina.aye@wrh.ox.ac.uk
Dr
Suchita
Nadkarni
s.nadkarni@qmul.ac.uk
Dr
Suchita
Nadkarni
s.nadkarni@qmul.ac.uk
Fetus and newborn affected by maternal factors and by complications of pregnancy, labour and deliveryCongenital malformations of the circulatory system
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Congenital heart disease (CHD) is the most common type of birth defect, affecting 1% of all pregnancies1. Despite the very early developmental stages of cardiac formation, with some cases of CHD detected at initial maternity booking scan (11-14weeks), the diagnosis of most CHDs does not occur until the 2nd trimester, between 18 and 22 weeks.
Based on our previously published data, we hypothesise that the maternal immune system plays a pivotal role in the development of the fetal heart. Specifically, underlying maternal inflammation early in pregnancy negatively impacts placental development, which in turn leads to congenital heart anomalies in the developing fetus. Thus, indications of maternal inflammation in the first trimester of pregnancy could pave the way for biomarkers for the early prediction of fetal congenital heart diseases (CHD) and identify potential therapeutic targets and non-invasive interventions. To address our hypothesis, we will undertake 2 main aims:
1. A retrospective cohort study to identify inflammatory markers in the maternal circulation within the first trimester of pregnancy from a cohort of confirmed fetal CHD cases and healthy controls, utilising stored Booking Blood samples taken at 10 weeks of pregnancy.
2. An observational cohort study to analyse the immune cell status from maternal blood samples at the 20 week scan, when a fetal CHD has been confirmed and analyse placental tissue at time of delivery for inflammatory and structural changes
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
• Unwilling or unable to give consent • Participants who are unable to understand written English • Confirmed diagnosis of baby having Down Syndrome
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Christina
Aye
christina.aye@wrh.ox.ac.uk
Dr
Suchita
Nadkarni
s.nadkarni@qmul.ac.uk
Dr
Suchita
Nadkarni
s.nadkarni@qmul.ac.uk
The study is sponsored by Queen Mary University of London and funded by Heart Research UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 63104
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
